Celldex Therapeutics Inc. (Nasdaq: CLDX) ended a Phase 3 clinical trial of its brain cancer vaccine Rintega. Shares of the biopharmaceutical plunged $4.42 to $3.77.
Celldex ends clinical trial
March 07, 2016 at 14:20 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.